Melbourne, Feb 11, 2008 AEST (ABN Newswire) - Biota Holdings Limited (ASX: BTA) today announced that its long acting neuraminidase inhibitor (LANI), CS8958, an antiviral influenza treatment, has completed enrolment for its Phase II clinical study in Japan. The Phase II trial commencement was advised in an ASX Release on 22 November 2007.
Biota CEO, Peter Cook said "Early onset of the influenza season in Japan has assisted us in achieving rapid patient enrolment for this study. Enrolment admission to the study was always going to be a critical element in the length of this clinical trial".
Contact
Peter Cook
T: +61 3 9915 3720
Damian Lismore
T: +61 3 9915 3721
| ||
|
